Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research

被引:287
作者
Chen, Xin [1 ,2 ]
Calvisi, Diego F. [3 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Liver Ctr, San Francisco, CA 94143 USA
[3] Ernst Moritz Arndt Univ Greifswald, Inst Pathol, Greifswald, Germany
关键词
IN-VIVO CORRECTION; TYROSINEMIA TYPE-I; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; GENE-EXPRESSION; BETA-CATENIN; INTRAHEPATIC CHOLANGIOCARCINOMA; MOLECULAR PATHOGENESIS; SOMATIC INTEGRATION; WNT/BETA-CATENIN;
D O I
10.1016/j.ajpath.2013.12.002
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Primary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are leading causes of cancer-related death worldwide. Recent large-scale genomic approaches have identified a wide number of genes whose deregulation is associated with hepatocellular carcinoma and intrahepatic cholangiocarcinoma development. Murine models are critical tools to determine the oncogenic potential of these genes. Conventionally, transgenic or knockout mouse models are used for this purpose. However, several limitations apply to the latter models. Herein, we review a novel approach for stable gene expression in mouse hepatocytes by hydrodynamic injection in combination with Sleeping Beauty-mediated somatic integration. This method represents a flexible, reliable, and cost-effective tool to generate preclinical murine models for liver cancer research. Furthermore, it can be used as an in vivo transfection method to study biochemical cross talks among multiple pathways along hepatocarcinogenesis and to test the therapeutic potential of drugs against liver cancer.
引用
收藏
页码:912 / 923
页数:12
相关论文
共 103 条
[1]  
AbouElella A, 1996, MODERN PATHOL, V9, P95
[2]   The AAV Vector Toolkit: Poised at the Clinical Crossroads [J].
Asokan, Aravind ;
Schaffer, David V. ;
Samulski, R. Jude .
MOLECULAR THERAPY, 2012, 20 (04) :699-708
[3]   Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace [J].
Baffy, Gyoergy ;
Brunt, Elizabeth M. ;
Caldwell, Stephen H. .
JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1384-1391
[4]   Mouse models for liver cancer [J].
Bakiri, Latifa ;
Wagner, Erwin F. .
MOLECULAR ONCOLOGY, 2013, 7 (02) :206-223
[5]   Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages [J].
Bibby, MC .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) :852-857
[6]   Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment [J].
Blechacz, Boris ;
Gores, Gregory J. .
HEPATOLOGY, 2008, 48 (01) :308-321
[7]   Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma [J].
Braconi, Chiara ;
Swenson, Erica ;
Kogure, Takayuki ;
Huang, Nianyuan ;
Patel, Tushar .
PLOS ONE, 2010, 5 (12)
[8]   Strategies for Hepatocellular Carcinoma Therapy and Diagnostics: Lessons Learned from High Throughput and Profiling Approaches [J].
Breuhahn, Kai ;
Gores, Gregory ;
Schirmacher, Peter .
HEPATOLOGY, 2011, 53 (06) :2111-2120
[9]  
Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185
[10]   Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo [J].
Bunting, KD ;
Zhou, S ;
Lu, TH ;
Sorrentino, BP .
BLOOD, 2000, 96 (03) :902-909